Polifarma expands its portfolio in the cardiovascular field with Almarytm and Icomb

Polifarma continues its growth in the cardiovascular sector with the addition of two new drugs to its portfolio: Almarytm and Icomb. The introduction of these products strengthens the therapeutic offering with the goal of providing doctors with comprehensive tools for managing cardiovascular diseases.

Almarytm: a reference in the treatment of arrhythmias

Thanks to its partnership with Viatris, Polifarma will manage the medical-scientific information for Almarytm, a key molecule in the treatment of arrhythmias. This drug is an important therapeutic choice for cardiologists and addresses the needs of those suffering from heart rhythm disorders.

Arrhythmia is one of the most complex and widespread conditions, with a significant impact on public health: promoting a well-established and proven therapy means making a concrete contribution to improving healthcare, complementing Polifarma’s cardiovascular therapeutic offering.

Icomb: the return of an essential drug for hypertension

Polifarma brings Icomb back to the market, a well-known and appreciated drug for treating hypertension, which has been a leader in the ramipril-amlodipine combination segment.

Hypertension is a condition affecting millions of people and is one of the main cardiovascular risk factors. Current guidelines recommend the use of fixed-dose combinations to improve therapeutic adherence and blood pressure control, and in this context, Icomb stands as a highly valuable option.

The decision to reintegrate Icomb into Polifarma’s portfolio stems from a thorough market analysis and the desire to offer a concrete response to a widespread therapeutic need. With a structured relaunch plan and widespread distribution, Polifarma aims to regain the market share previously held by the drug, ensuring therapeutic continuity for patients and providing doctors with an effective tool for treating hypertension.

A step forward in Polifarma’s vision

The integration of Almarytm and Icomb into the portfolio is part of a broader growth and development plan that includes the implementation of new therapeutic solutions and the adoption of innovative tools for managing cardiovascular diseases.

The evolution of the healthcare sector requires dynamic and responsive companies that can anticipate needs and respond swiftly: Polifarma is ready to take on this challenge, with passion, expertise, and a clear vision for the evolution of cardiovascular health.